Our study further elucidated that CYP2J2/EET exerts its effects by PPAR‐γ activation, thereby inhibiting atrial fibrosis through targeting MiR‐21/Smad‐7 and diminishing inflammatory response by inactivation of NFκB pathways, leading to the reduction in AF vulnerability. The gene discussed is SMAD7; the disease is atrial fibrillation.